Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?
Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?
复制标题
DOI：
10.1016/j.critrevonc.2012.08.003
复制
发表时间：
2012-12-01
影响因子：
6.2
通讯作者：
Desmedt, Christine
中科院分区：
文献类型：
--
作者：
Fumagalli, Debora;Andre, Fabrice;Desmedt, Christine
乳腺癌是一种复杂的疾病，具有异质性的表现和临床过程。标准临床病理参数依赖于有时重复性差的技术确定的单基因或蛋白质特征，在疾病分类以及预测个体患者结果和治疗反应方面显示出局限性。基因表达谱揭示了准确分类乳腺癌、确定患者预后和预测抗癌治疗的巨大潜力。然而，分子分类器的性能仍然不够理想，需要技术和概念上的改进。确定乳腺癌治疗的理想策略可能需要比过去更加系统、结构化和多维的方法。除了采用尖端技术来检测遗传和表观遗传癌症改变之外，乳腺癌研究的未来很可能依赖于分子谱与疾病临床参数和患者相关因素的创新和多层次整合。 (C) 2012 年，爱思唯尔爱尔兰有限公司出版。
Breast cancer is a complex disease, with heterogeneous presentations and clinical courses. Standard clinico-pathological parameters, relying on single gene or protein characterization determined with sometimes poorly-reproducible technologies, have shown limitations in the classification of the disease and in the prediction of individual patient outcomes and responses to therapy. Gene-expression profiling has revealed great potential to accurately classify breast cancer and define patient prognosis and prediction to anti-cancer therapy. Nevertheless, the performance of molecular classifiers remains sub-optimal, and both technical and conceptual improvements are needed. It is likely that determining the ideal strategy for tailoring treatment of breast cancer will require a more systematic, structured and multi-dimensional approach than in the past. Besides implementing cutting-edge technologies to detect genetic and epigenetic cancer alterations, the future of breast cancer research will in all probability rely on the innovative and multilevel integration of molecular profiles with clinical parameters of the disease and patient-related factors. (C) 2012 Published by Elsevier Ireland Ltd.